The Canadian Cancer Action Network (CCAN), in collaboration with CADTH, is pleased to invite you to a free, interactive workshop on how cancer drugs are reviewed through CADTH’s pan-Canadian Oncology Drug Review (pCODR) process.
October 25, 2016, 1:00 p.m. to 4:00 p.m., Grand Hotel & Suites Toronto, 225 Jarvis St, Toronto, Ontario
RSVP: Please confirm your attendance at this workshop session via email at firstname.lastname@example.org, by October 20, 2016.
This is an opportunity for participants to:
- Meet with the Health Technology Assessment Patient Engagement Navigator (HTAPEN), and become familiar with the resources and tools available to support a patient submission to pCODR
- Get best practices, tips, and advice on how to plan and make a patient submission to pCODR
- Understand how cancer drugs are approved in Canada, with a focus on the pCODR process
- Learn how costs and benefits are considered in the health technology assessment (HTA) process, with a focus on cancer drugs
- Obtain insight directly from the patient members of the pCODR Expert Review Committee (pERC) on how patient evidence and information make a difference to the Committee’s recommendations.
Participants will have an opportunity to take part in a case study to understand the HTA recommendation process and to gain insight on how HTA committees make a funding recommendation for a cancer drug. Participants will have the chance to follow the deliberative framework used by pERC, which examines the overall clinical benefit, alignment of patient values, cost-effectiveness, and implementation considerations.
We encourage you to review the Tutorial: How Cancer Drug Funding Decisions Are Made, to help you get the most from the workshop.